EPI-743 in Friedreich's Ataxia Point Mutations

Completed · Phase 2

Conditions studied: Friedreich's Ataxia

In brief

The purpose of this study is to evaluate the effects of EPI-743 in patients with Friedreich's Ataxia point mutations

Key facts

Study ID

NCT01962363

Run by

University of South Florida

People needed

4

Starts

2013-10-01

Expected to finish

2016-06-01

Last updated by the study team

2016-06-29

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of genetically confirmed Friedreich's ataxia point mutation.
• Visual acuity at baseline more than 15 letters on high contrast EDTRS at four meters.
• FARS score of 20 to 90.
• Male or female between 18 and 65 years of age.
• Agreement to use contraception if within reproductive years
• Hormone replacement therapy, if used, must remain stable for the duration of the study.
• Willingness and ability to comply with study procedures.
• Willingness and ability to arrive at study site metropolitan area day prior to evaluations.
• Abstention from use of dietary supplements and non-prescribed medications at least 30 days prior to initiation of treatment and for the duration of the study. This would specifically include idebenone, Coenzyme Q10 and vitamin E.
• Abstention from foods or beverages or bars fortified with Coenzyme Q10, vitamin E, super fortified functional foods or beverages at least 30 days prior to initiation of treatment and for the duration of the study.
• Abstention from use of other investigative or non-approved drugs within 30 days of enrollment and for the duration of the study.
• Subject can swallow multiple size 0 capsules.
• Subject has voluntarily signed an IRB approved informed consent form to participate in the study after all relevant aspects of the study have been explained and discussed with the subject.

You may not qualify if…

• Allergy to EPI-743 or sesame oil or nuts.
• Clinically significant bleeding condition or abnormal PT/PTT INR (INR > two; PTT > two-times normal).
• Liver insufficiency with LFTs greater than three-times upper normal limit at screening.
• Renal insufficiency with creatinine > 1.5 at screening.
• Fat malabsorption syndromes.
• Any other respiratory chain diseases of the mitochondria or inborn errors of metabolism.
• Any other ophthalmologic conditions.
• Clinically significant cardiomyopathy with ejection fraction < 40 percent at screening.
• Clinically significant arrhythmia within past two years requiring treatment.
• Surgery planned through the duration of the study, including follow-up.
• Pregnancy or breastfeeding.
• Anticoagulant therapy within 30 days of enrollment.

Where it is running

• University of South Florida — Tampa, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.